Back to Results
First PageMeta Content
Genetic genealogy / BioMarin Pharmaceutical / Duchenne muscular dystrophy / Dystrophin / 3 / 4-Diaminopyridine / Mucopolysaccharidosis / Morquio syndrome / Tetrahydrobiopterin / Muscular dystrophy / Health / Biology


Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc[removed]
Add to Reading List

Open Document

File Size: 354,45 KB

Share Result on Facebook

City

Leiden / Washington / DC / Darmstadt / RAFAEL / /

Company

BioMarin Pharmaceutical Inc. / Parent Project Muscular Dystrophy / Merck Serono / Prosensa N.V. / Merck KGaA / Genzyme Corporation / Media Debra Charlesworth BioMarin Pharmaceutical Inc. / Investors Traci McCarty BioMarin Pharmaceutical Inc. / Prosensa Holding N.V. / /

Continent

Europe / /

Country

Germany / Netherlands / United States / /

Currency

USD / /

Event

Reorganization / FDA Phase / M&A / Conference Call / Business Partnership / General or Shareholder Meeting / Security Buyback / /

Facility

Prosensa’s pipeline / Prosensa’s headquarters / /

IndustryTerm

rare disease therapies / near-term opportunity / biotechnology / treatment of germline BRCA breast cancer / treatment of Lambert Eaton Myasthenic Syndrome / treatment of Pompe disease / therapeutics for the treatment of genetic disorders / preclinical products / potential products / therapies for people with devastating disorders / /

MedicalCondition

muscular dystrophy / rare diseases / progressive muscle weakness / late-infantile neuronal ceroid lipofuscinosis / common fatal genetic disorder / germline BRCA breast cancer / Huntington’s disease / Parent Project Muscular Dystrophy / Lambert Eaton Myasthenic Syndrome / achondroplasia / phenylketonuria / Pompe disease / rare neuromuscular and neurodegenerative disorders / serious diseases / mucopolysaccharidosis VI / Project Muscular Dystrophy / myotonic dystrophy / rare disease / prominent rare disease / mucopolysaccharidosis I / fatal genetic disorder / PKU / rare / fatal genetic disease / Batten Disease / deficiency / disorders / genetic disorders / /

MedicalTreatment

innovative therapies / /

Organization

Food and Drug Administration / Prosensa’s mission / European Commission / FDA / Securities and Exchange Commission / /

Person

Jean-Jacques Bienaimé / Lambert Eaton Myasthenic / Pat Furlong / Hans Schikan / /

/

Position

Chief Executive Officer / President and Founder / General / leader / general meeting / /

Product

Aldurazyme / KUVAN / Naglazyme / Naglazyme® (galsulfase) / CLN2 / /

ProvinceOrState

California / /

Technology

alpha / biotechnology / biopharmaceuticals / SAN / /

URL

www.sec.gov / www.BMRN.com / www.ParentProjectMD.org / /

SocialTag